{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:17Z","timestamp":1775488097396,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD) are at higher risk of developing malignancies, including neuroendocrine neoplasms, but the specifics of that are not well known. We reviewed the existing literature to map the evidence surrounding this phenomenon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following PRISMA 2020 guidelines, we searched PubMed from inception to September 2024 for patients with gastrointestinal neuroendocrine neoplasms (NENs) and either Crohn disease (CD) or ulcerative colitis (UC). Eligible studies included case reports, case series, and larger retrospective IBD cohorts. We extracted demographic and clinical data including tumor grade, location, metastatic status, and mode of detection. Comparative analyses between UC and CD were performed using Fisher exact test, chi-square test, and independent t-tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We identified 67 case studies with data available for a total of 108 patients (61.1% male), ranging from 14 to 87 years of age. The median duration from IBD diagnosis to NEN detection was 13 years. Fifty-five (50.9%) patients had CD and 53 (49.1%) had UC. UC patients were older at NEN diagnosis (mean 49 vs 40 years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.004) and had a higher metastatic rate (39.6% vs 18.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.019). Most NENs were low-grade (69.4%), while 20.4% were high-grade and 8.3% were mixed. The most common tumor locations were the rectum (29.6%) and appendix (27.8%), with rectal and colonic NENs more prevalent in UC and small bowel or appendiceal NENs more common in CD. At diagnosis, 71.3% of patients had localized disease. For high-grade NENs, 86.4% of cases were metastatic, compared to 9.3% for low-grade tumors. Only 10.2% of NENs were detected via endoscopic surveillance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>NENs in IBD show distinct patterns by IBD type, with significant differences in tumor location, grade, and metastatic rates between UC and CD. These hypothesis-generating observations suggest heightened vigilance after approximately 10 years of IBD or around age 44, focusing on rectal lesions in UC and small bowel\/appendiceal lesions in CD. Validation in prospective, population-based studies is needed before these findings can inform clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048150","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:00:51Z","timestamp":1775232051000},"page":"e48150","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Neuroendocrine neoplasms diagnosed in the setting of inflammatory bowel disease: A systematic review and proposed management algorithm"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-2173","authenticated-orcid":false,"given":"Mohamed M.","family":"Khamis","sequence":"first","affiliation":[{"name":"Department of Medicine, Mercy Hospital St. Louis, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6666-8576","authenticated-orcid":false,"given":"Imad","family":"Karam","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, State University of New York (SUNY) Downstate Medical Center, Brooklyn, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel D.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Washington University, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-2182","authenticated-orcid":false,"given":"Nikolaos A.","family":"Trikalinos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"1376123","DOI":"10.3389\/fgene.2024.1376123","article-title":"Identification of TIMP1-induced dysregulation of epithelial-mesenchymal transition as a key pathway in inflammatory bowel disease and small intestinal neuroendocrine tumors shared pathogenesis.","volume":"15","author":"Tran","year":"2024","journal-title":"Front Genet"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system.","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ijc.30096","article-title":"Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease?","volume":"139","author":"Derikx","year":"2016","journal-title":"Int J Cancer"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.annonc.2022.02.226","article-title":"Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel.","volume":"33","author":"Yu","year":"2022","journal-title":"Ann Oncol"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/ecco-jcc\/jjab076.251","article-title":"Gastroenteropancreatic neuroendocrine neoplasms in patients with inflammatory bowel disease: an ECCO CONFER multicentre case series.","volume":"15","author":"Festa","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.cgh.2017.06.051","article-title":"Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study.","volume":"15","author":"Bojesen","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MEG.0000000000001693","article-title":"Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.","volume":"32","author":"Basarano\u011flu","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R11-20260406","first-page":"111","article-title":"Colorectal Cancer Screening and Surveillance in Individuals at Increased Risk.","volume":"97","author":"Wilkins","year":"2018","journal-title":"Am Fam Physician"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/ecco-jcc\/jjv177","article-title":"Extensive neuroendocrine adenocarcinoma in ulcerative colitis.","volume":"10","author":"Carvalho","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"e247069","DOI":"10.6004\/jnccn.2024.7069","article-title":"Do appendiceal neuroendocrine tumors metastasize post appendectomy or right hemicolectomy?","volume":"23","author":"Al-Toubah","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11912-023-01484-4","article-title":"Appendiceal neuroendocrine neoplasms: an update for 2023.","volume":"26","author":"Holmager","year":"2024","journal-title":"Curr Oncol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:19Z","timestamp":1775484079000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":13,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048150","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-11-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}